Symbols

MDWD

MediWound·NASDAQ

--(--)

MDWD fundamentals

MDWD Q4 2025 Earnings

MediWound (MDWD) released its earnings on Mar 5, 2026: revenue was 1.87M (YoY -68.03%), missed estimates; EPS was -0.56 (YoY -55.56%), beat estimates.

Revenue / YoY

1.87M

-68.03%

EPS / YoY

-0.56

-55.56%

Report date

Mar 5, 2026

MDWD Earnings Call Summary for Q4,2025

Clinical Momentum: EscharEx Phase III VLU trial on track for 2026 completion; DFU and pressure ulcer trials expanding addressable market.
Manufacturing Scale-Up: NexoBrid capacity increased sixfold, positioning for 2026 commercial launch.
Financial Resilience: $53.6M cash balance supports multiyear growth despite 2025 revenue decline to $17M.
Strategic Partnerships: B. Braun collaboration enhances EscharEx clinical validation; 7+ wound care partners support trial execution.
Revenue Outlook: 2026 guidance ($24-26M) reflects BARDA/DOD funding and NexoBrid ramp-up, with 2028 target of $50-55M.

Earnings

EPS

Revenue

Revenue & Expenses

MDWD has released its 2025 Q4 earnings report, with revenue of 1.87M, reflecting a YoY change of -68.03%, and net profit of -7.18M, showing a YoY change of -83.80%. The Sankey diagram below clearly presents MDWD's revenue sources and cost distribution.

Key Indicators

MediWound (MDWD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

MediWound (MDWD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

MediWound (MDWD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

MediWound (MDWD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown